US Patent

US9095609 — Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia

Method of Use · Assigned to Consejo Superior de Investigaciones Cientificas CSIC · Expires 2031-09-08 · 5y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects ophthalmic compositions containing WS-12 and methods for treating dry eye and epiphora.

USPTO Abstract

The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Drugs covered by this patent

Tryptyr (ACOLTREMON) · Alcon Labs Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1900`	—	Tryptyr

Patent Metadata

Patent number: US9095609
Jurisdiction: US
Classification: Method of Use
Expires: 2031-09-08
Drug substance claim: No
Drug product claim: Yes
Assignee: Consejo Superior de Investigaciones Cientificas CSIC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.